全文获取类型
收费全文 | 5651篇 |
免费 | 236篇 |
国内免费 | 30篇 |
专业分类
耳鼻咽喉 | 48篇 |
儿科学 | 89篇 |
妇产科学 | 32篇 |
基础医学 | 649篇 |
口腔科学 | 121篇 |
临床医学 | 368篇 |
内科学 | 1177篇 |
皮肤病学 | 150篇 |
神经病学 | 685篇 |
特种医学 | 338篇 |
外科学 | 880篇 |
综合类 | 28篇 |
预防医学 | 187篇 |
眼科学 | 185篇 |
药学 | 559篇 |
中国医学 | 8篇 |
肿瘤学 | 413篇 |
出版年
2022年 | 57篇 |
2021年 | 76篇 |
2020年 | 47篇 |
2019年 | 56篇 |
2018年 | 64篇 |
2017年 | 60篇 |
2016年 | 68篇 |
2015年 | 79篇 |
2014年 | 103篇 |
2013年 | 134篇 |
2012年 | 177篇 |
2011年 | 243篇 |
2010年 | 145篇 |
2009年 | 118篇 |
2008年 | 210篇 |
2007年 | 221篇 |
2006年 | 216篇 |
2005年 | 227篇 |
2004年 | 251篇 |
2003年 | 268篇 |
2002年 | 254篇 |
2001年 | 238篇 |
2000年 | 267篇 |
1999年 | 224篇 |
1998年 | 79篇 |
1997年 | 66篇 |
1996年 | 49篇 |
1995年 | 49篇 |
1994年 | 48篇 |
1993年 | 50篇 |
1992年 | 174篇 |
1991年 | 162篇 |
1990年 | 151篇 |
1989年 | 139篇 |
1988年 | 131篇 |
1987年 | 117篇 |
1986年 | 106篇 |
1985年 | 115篇 |
1984年 | 80篇 |
1983年 | 57篇 |
1982年 | 33篇 |
1979年 | 56篇 |
1978年 | 32篇 |
1977年 | 34篇 |
1975年 | 30篇 |
1974年 | 41篇 |
1973年 | 31篇 |
1971年 | 29篇 |
1968年 | 28篇 |
1967年 | 28篇 |
排序方式: 共有5917条查询结果,搜索用时 12 毫秒
1.
Hori Hiroki Ohta Asuka Matsui Honami Yano Kanako Morita-Tominaka Miyuki Linn Zayar Masumoto Daisuke Okumura Yosuke Okamura Satoshi Kurihara Kosuke Hayakawa Akira Rikiishi Takeshi Kobayashi Kyoko 《International journal of clinical oncology / Japan Society of Clinical Oncology》2022,27(1):245-252
International Journal of Clinical Oncology - The practice of cancer diagnosis disclosure to children has been changed with the times. The regulations of clinical trials in the 2000s might change... 相似文献
2.
3.
Induction of endothelium-dependent relaxation in the rat aorta by IRL 1620, a novel and selective agonist at the endothelin ETB receptor. 总被引:3,自引:2,他引:1
下载免费PDF全文
![点击此处可从《British journal of pharmacology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
H. Karaki S. A. Sudjarwo M. Hori M. Takai Y. Urade T. Okada 《British journal of pharmacology》1993,109(2):486-490
1. The effects of a novel and selective agonist at the endothelin ETB receptor, IRL 1620 (Suc-[Glu9, Ala11,15] endothelin-1 (8-21)), were examined in the isolated aorta of the rat. 2. IRL 1620 (1-300 nM) changed neither the resting tone nor the cytosolic Ca2+ level ([Ca2+]i) of the aorta without endothelium. In the presence of endothelium, however, IRL 1620 increased endothelial [Ca2+]i with little effect on the muscle tone. In the absence of external Ca2+, IRL 1620 still induced a transient increase in endothelial [Ca2+]i. 3. Noradrenaline (100 nM) increased both muscle [Ca2+]i and tension. IRL 1620 (1-300 nM) relaxed the muscle with an increase in endothelial [Ca2+]i only in the presence of endothelium. An inhibitor of nitric oxide synthase, 100 microM NG-monomethyl-L-arginine, inhibited the relaxant effect of IRL 1620 but not the increase in endothelial [Ca2+]i. 4. In resting and noradrenaline-stimulated aorta, the effects of IRL 1620 were inhibited by a selective antagonist of the ETB receptor, IRL 1038 (0.3-3 microM), although a selective antagonist of the ETA receptor, BQ-123 (3 microM), was ineffective. Verapamil (10 microM) did not alter the effects of IRL 1620. 5. A muscarinic receptor agonist, carbachol (1 microM), also induced endothelium-dependent relaxation with an increase in endothelial [Ca2+]i. However, the effects of carbachol were not inhibited by the ETB antagonist, IRL 1038 (3 microM).(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
4.
Immunosuppressive activities of the newly discovered FK506, isolated from Streptomyces tsukubaensis, were examined by using cardiac allotransplantation in the rat, and the mechanisms underlying induction and maintenance of FK506-induced long-term allograft survival were studied. Male rats of WKA (RT1k) and F344 (RT1lvl) strains were used as recipients and donors, respectively, and those of BN (RT1n) strain were used as third-party donors. Treatment with FK506, beginning from the day of allografting for 14, 10, or as few as 4 days, prolonged allograft survival significantly across the major histocompatibility barrier. The minimum doses for prolonging graft survival were 0.1 mg/kg/day by intramuscular treatment and 1.0 mg/kg/day by oral treatment. Treatment with FK506 at a dose of 0.32 mg/kg/day from day 4 until day 10 resulted in all the grafts surviving indefinitely and from days 5 to 10, half the grafts survived indefinitely, suggesting that the agent inhibited ongoing rejection. On the other hand, cyclosporine treatment at a dose of 20 mg/kg/day from day 2 did not prolong graft survival time statistically significantly. Induction of prolonged graft survival was not obtained by pretreatment of the prospective donor or recipient; prolonging effects were observed only when the agent was administered after allografting. Thus, the primary effect of the agent is exerted on responder lymphocytes reacting to the donor antigens in the induction phase of long-term graft acceptance. The mechanisms underlying the maintenance of long-term grafts were analyzed by testing the capacity of lymphocytes or serum of long-term graft-bearing rats to inhibit graft rejection in irradiated grafted hosts. Transfer of 2 x 10(8) lymphocytes from FK506-induced long-term F344 graft-bearing WKA rats resulted in indefinite survival of F344 heart allografts, but it did not prolong survival of third-party BN hearts. Transfer of 2.5 ml serum from long-term graft-bearing rats also prolonged graft survival of F344 hearts, but not BN hearts. These results suggest that donor strain-specific suppressor cells and humoral factor(s) are induced by treatment with FK506 in the presence of allografts, and that they play at least partial roles in the maintenance of long-term allograft acceptance. 相似文献
5.
The estimation of breakthrough time for multicomponent organic solvent vapors on activated carbon fixed beds is significantly complicated and difficult. This paper describes a simple estimation method of breakthrough time for the first component (foremost breakthrough component) in two- or three-component organic solvent vapors on an activated carbon fixed bed. The breakthrough time for the first component was expressed by the harmonic mean value of the breakthrough times in each pure component. Estimated breakthrough times were compared with the experimental ones. 相似文献
6.
Effects of halothane on spinal dorsal horn WDR(wide dynamic range) neuronal activity in cats 总被引:1,自引:0,他引:1
H Nagasaka S Nakamura T Genda T Miyazaki K Aikawa N Matsumoto I Matsumoto T Hori I Sato 《Masui. The Japanese journal of anesthesiology》1991,40(7):1096-1101
The effects of halothane (0.2%, 0.5%, and 1.0%) on the spinal dorsal horn wide dynamic range (WDR) neuronal activity was studied in either spinal cord intact or spinal transected cats. Extracellular activity was recorded in the dorsal horn from single WDR neurons responding to noxious and non-noxious stimuli applied to the cutaneous receptive fields on the left hind foot pads of intact or decerebrate, spinal cord transected (L 1-2) cats. When 10 micrograms of bradykinin was injected into the femoral artery ipsilateral to the recording site as the noxious test stimulus in the spinal cat, all of 7 WDR neurons gave excitatory responses which were not depressed by 0.2% and 0.5% halothane but were depressed significantly by 1.0%. On the other hand, when the injection of 10 micrograms of bradykinin into the femoral artery ipsilateral to the recording site was used in the intact cat, 7 of 14 WDR neurons (50%) gave excitatory responses, which were not depressed by 0.2% halothane but were significantly depressed by 0.5% and 1.0% halothane, and 7 of 14 WDR neurons (50%) gave inhibitory responses, which were significantly depressed by 0.2%, 0.5%, and 1.0% halothane. We have found that halothane reduces the excitation as well as the inhibition of dorsal horn WDR neuronal activity induced by bradykinin injection. 相似文献
7.
A T Farrell I Papadouli A Hori M Harczy B Harrison W Asakura M Marty R Dagher R Pazdur 《Annals of oncology》2006,17(6):889-896
PURPOSE: This paper summarizes the role of external advisors in oncology drug development and regulation from a global perspective. DESIGN: Recently, representatives from the United States Food and Drug Administration, European Medicines Agency, the Japanese Pharmaceuticals and Medical Devices Agency, the Australian Therapeutic Goods Administration and Health Canada held a meeting in conjunction with the American Society of Clinical Oncology meeting. The role of external advisors in oncology drug development and regulation in each of these jurisdictions was presented and discussed. RESULTS: All regulatory bodies described have experience with two forms of outside expertise: advice from individual experts and advice from a group of experts assembled as an advisory group. Regulatory jurisdictions use individual experts variably. In some regions, individual experts provide advice based on knowledge and experience during the drug development phase or in the planning phase for the submission of a drug registration package. In other regions, these individuals serve as external evaluators with the primary responsibility for the review of a clinical trials package submitted for drug registration. Advisory boards have been formalized in all jurisdictions discussed. Advisory boards have a role in discussing specific applications as well as broad policy issues. A common theme is a composition of a core panel of experts with augmentation by additional expertise as needed for consideration of specific scientific questions. In all jurisdictions, advisory board recommendations are not binding on the regulatory body. CONCLUSIONS: Global oncology drug development and registration involves the use of experts by regulatory authorities. The types of experts needed, the expert's role and the transparency of the advisory process reflect the individual needs in different regions. 相似文献
8.
Shinichiro Yasumoto Jun Tsujita Shuhei Imayama Yoshiaki Hori 《The Journal of dermatology》1996,23(7):499-501
We report a case of Gianotti-Crosti syndrome associated with human herpesvirus-6 (HHV-6) infection. An eight-month-old girl developed monomorphous papules on her cheeks, buttocks, and extremities after the subsidence of exanthema subitum. Viral antibody analysis confirmed primary HHV-6 infection. HHV-6 may be added to the list of causative agents of Gianotti-Crosti syndrome. 相似文献
9.
M Higashigawa Y Komada N Washio H Kuwabara H Hori M Ido M Sakurai 《Leukemia research》1992,16(10):1049-1054
In vitro preincubation with recombinant granulocyte colony-stimulating factor(rhG-CSF, 100 ng/ml) enhanced the cytotoxicity of 1-beta-D-arabinofuranosylcytosine(Ara-C) in leukemic cells resistant to Ara-C from a patient with biphenotypic leukemia. Treatment of the cells with rhG-CSF resulted in a 17-fold increase in DNA synthesis, 4.6-fold increase in percentage of S-phase, and a two-fold increase in Ara-CTP formation. Maximal effect was observed at 72 h of incubation. Combination chemotherapy with rhG-CSF and Ara-C to the patient showed remarkable cytoreduction. These results indicate that recruitment of resistant leukemic cells in cell kinetic quiescence is inducible by rhG-CSF and that it is possible enhancement of the cytotoxicity to cell cycle-specific drugs such as Ara-C. 相似文献
10.
Fuyumi Yamamoto Hiroshi Kasai Tadayoshi Bessho Myung-Hee Chung Hideo Inoue Eiko Ohtsuka Tomokatsu Hori Susumu Nishimura 《Cancer science》1992,83(4):351-357
Here we report the finding of enzymatic activity that specifically cleaves DNA containing 8-hydroxyguanine (oh8 Gua) residues in various mammalian cells. To detect this activity, we used a synthetic double-stranded DNA containing a single oh8 Gua at a defined position as the substrate, and analyzed the products of enzymatic digestion by polyacrylamide gel electrophoresis. Two cleavage sites near the oh8 Gua residue were detected with partially purified fractions from cow brain and rat liver, and also with preparations from all mammalian tissues examined. These results suggest that enzymatic activity for the removal of oh8 Gua from DNA is widely distributed in mammalian cells. 相似文献